Skip to main content
. 2021 Jan 29;8(6):2003091. doi: 10.1002/advs.202003091

Figure 4.

Figure 4

Tumor cell lytic capacity of anti‐CD38 RP02 and RP03 CAR‐T cells. a–c) Anti‐CD38 CAR‐T cells generated significantly stronger cytotoxicity for CD38+ target tumor cells (Daudi and RPMI8226) in comparison to mock T cells after coculturing for different incubation times, e.g., 24, 48, and 72 h at an effector:target (E:T) ratio of 4:1. Data are represented as the mean ± s.e.m. of n = 3 technical replicates. Significance was considered as *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.